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spirin for the Masses
he recent article by Joshi et al. (1) stressed the need for a
onphysician workforce in cardiovascular disease (CVD) manage-
ent in low- and middle-income countries. We believe that there
s a need to go one step further, considering the exigency of the
ituation. The use of aspirin for primary prevention is well
stablished and must be added to this approach at a community
evel. The combination of nonphysician health care workers
NPHWs) equipped with aspirin can potentially be a very effective
trategy. Aspirin is a drug of common social acceptance in
eveloping countries, is often readily available over the counter,
nd is easily affordable because most payments are out of pocket.
tatins and diuretics unfortunately do not share these attributes, at
east at present.
A program should be developed to teach the NPHWs thedministration of aspirin along with lifestyle modification after the bdentification of high-risk patients. This will not be easy, and a risk
ssessment tool would need to incorporate the risk of bleeding with
spirin. Routine availability of cholesterol and glucose evaluation at
he community level will remain elusive for years to come, and
linical criteria and clinical risk prediction models will have to be
elied upon. The use of a national cholesterol average as a
ubstitute is a decent suggestion in these calculations (2). The
orld Health Organization CVD risk management package has
een successfully practiced by NPHWs (3) and can be useful in
his regard.
Compliance, however, will still be the fundamental problem.
here is evidence to suggest that although interventions result in
mproved knowledge, they do not necessarily translate into practice
4). There is anecdotal evidence to suggest that people in these
ettings do not comply with medicines for which they see no overt
enefits. This necessitates that vessels of established trust be used,
here available, to spread prevention and proven intervention
and-in-hand to the current epidemic of CVD in developing
ountries.
There are many examples of effective health care delivery by
PHWs in developing world settings, such as the success of the
ntegrated Management of Childhood Illness program on an
nternational scale and the Lady Health Visitor program for female
ealth care in Pakistan (4). The latter can also serve to address the
ender inequity of health care access more effectively because of its
arge network, penetration, and reputation.
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eply
e thank Drs. Aslam and Waheed for their comments on our
ecent paper (1). They raise an important issue regarding the role
f nonphysician health care workers in the identification of
ndividuals at high risk of cardiovascular disease, such as those with
history of myocardial infarction or ischemic stroke, and their
anagement in the community with low-cost drugs such as
spirin. We agree that nonphysician health care workers
NPHWs) should be able to prescribe aspirin for secondary
revention, but we also believe that they should be able to prescribe
ther low-cost, low-risk, high-benefit treatments both for second-
ry prevention (e.g., blood pressure- and lipid-lowering drugs) and
or cardiovascular symptom management (e.g., nitrates, beta-
lockers) (2). Low-dose combination therapy for secondary pre-
